A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Alcon Research87 enrolled

Overview

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

AL-37807 Ophthalmic Suspension, 1.0%DRUG

One drop in the study eye(s) once daily for 28 days

Latanoprost, 0.005% (Xalatan)DRUG

One drop in the study eye(s) once daily for 28 days

AL-37807 VehicleOTHER

One drop in the study eye(s) once daily for 28 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment dispersion component) or ocular hypertension * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Under 18 * Other protocol-defined exclusion criteria may apply.

Locations (1)

United States Investigative Sites in Texas and Other States

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean intra-ocular pressure (IOP) change at Day 28 from baseline (Day 0)

Time frame: Day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.